These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9875670)

  • 21. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
    Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
    Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
    Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
    Singh R; Dominiecki ME; Jaffee EM; Paterson Y
    J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
    Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
    Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
    Knutson KL; Disis ML
    Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
    Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
    Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
    Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells.
    Burkhardt UE; Sloots A; Jakobi V; Wei WZ; Cavallo F; Kloke BP; Wels WS
    Cancer Immunol Immunother; 2012 Sep; 61(9):1473-84. PubMed ID: 22331080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice.
    Curcio C; Khan AS; Amici A; Spadaro M; Quaglino E; Cavallo F; Forni G; Draghia-Akli R
    Cancer Gene Ther; 2008 Feb; 15(2):108-14. PubMed ID: 17992201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
    Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
    Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
    Allen SD; Garrett JT; Rawale SV; Jones AL; Phillips G; Forni G; Morris JC; Oshima RG; Kaumaya PT
    J Immunol; 2007 Jul; 179(1):472-82. PubMed ID: 17579068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
    Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An anti-vascular endothelial growth factor receptor 2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis cancer vaccine for the treatment of primary and metastatic Her-2/neu+ breast tumors in a mouse model.
    Seavey MM; Maciag PC; Al-Rawi N; Sewell D; Paterson Y
    J Immunol; 2009 May; 182(9):5537-46. PubMed ID: 19380802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Fry EA; Taneja P; Inoue K
    Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.